All News

In this episode of Pearls & Perspectives, Amy Pearlman, MD, and plastic surgeon Andrew T. Cohen, MD, FACS, discuss managing patient expectations and the importance of cultivating balance outside of surgical practice.

Narmina Khanmammadova, MD, discusses interim findings on preoperative pelvic floor therapy and its potential to improve continence recovery after HoLEP.

Jessica Yih, MD, reviews evidence on testosterone therapy for female sexual dysfunction, highlighting promising but limited data in premenopausal women.

A claims-based analysis found blue light cystoscopy was associated with increase health care resource utilization in NMIBC without significantly increasing total costs.

A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

Elizabeth Nally, MBBS, highlights the impact of long-term immunotherapy toxicity and the need for patient-informed approaches to treatment decisions.

In this episode of The UroOnc Minute, Mark D. Tyson, II, MD, MPH, discusses the importance of BCG maintenance therapy in NMIBC and shares strategies for navigating treatment barriers and toxicity.

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.

Amy Pearlman, MD, and guests Larry Lipshultz, MD, and Elliot Justin, MD, explore the potential of wearable technology to advance the diagnosis, monitoring, and optimization of sexual health for both men and women.

The next-generation implant is designed to extend the implant longevity from 10 years to 15 years.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Alan Bryce, MD, breaks down the key prostate cancer studies that he believes are going to change practice from ASCO 2026.

OMCAZIO demonstrated bioequivalence to CABOMETYX at a lower dose and was found to have no clinically significant food effect.

Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.

Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.

The approval is supported by data from the phase 3 PSMAddition trial.

Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.

A reference on the key recommendations from the AUA Testosterone Deficiency guideline.

AI in medicine is here. What happens next matters for the future of health care delivery.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

In this episode, Gabe Canales reflects on his journey receiving a diagnosis of prostate cancer at a young age and emphasizes the importance of patient advocacy.

Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.

Adanma Ayanambakkam, MD, MS, highlights data from the phase 1 FIT-001 trial evaluating darlifarnib plus cabozantinib in patients with advanced renal cell carcinoma.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

Phase 3 BOND-003 data published in The Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.